13 million euros for Mbiomics: The Munich-based biotech company Mbiomics, which develops microbiome-based therapeutics, secures a Series A over 13 million eurosIn addition to Bayern Kapital, MIG Capital as lead investor, as well as High-Tech Gründerfonds and other private investors participated in the first closing of the round.